STAT+: Pharmalittle: We’re reading about another AstraZeneca trial failure, a Novo name change, and more

Written and edited by the WorldPing NewsdeskPublished Updated Original reporting: STAT
STAT+: Pharmalittle: We’re reading about another AstraZeneca trial failure, a Novo name change, and moreWorldPing
Image via STAT.

What happened

AstraZeneca disclosed that a breast cancer pill failed in a pivotal trial testing it as a first-line therapy in advanced tumors…

Key facts

  • AstraZeneca disclosed that a breast cancer pill failed in a pivotal trial testing it as a first-line therapy in advanced tumors…
  • Reported by STAT and published Mon, 14 Sep 2026 13:07:51 UTC.

Why it matters

Outbreaks, approvals and guidance changes have direct practical consequences for care, travel and public-health planning.

What to watch next

  • Case numbers and official guidance updates
  • Regulatory decisions in other countries
  • Supply, recall or access changes

Coverage timeline

When each newsroom published on this story, oldest first — all times UTC.

  1. STAT+: Definium’s LSD therapy eased anxiety in second large trial

  2. STAT+: Pharmalittle: We’re reading about another AstraZeneca trial failure, a Novo name change, and more

Sources

The original report was published by STAT. WorldPing does not claim that reporting — this page summarises and contextualises it.

Read the full report at STAT

Related WorldPing coverage

Why is everyone suddenly worried about the risks of AI?WorldPing
New Scientist

Why is everyone suddenly worried about the risks of AI?

AI experts put the chance of models rising up and killing us all at greater than 10 per cent – but are the risks real? And can anything be done if they are?

Brief by WorldPing · Original reporting by New Scientist